Tenaya Therapeutics Reports Promising Interim Data on Gene Therapy for HCM
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: NASDAQ.COM
- Clinical Trial Progress: Tenaya Therapeutics presented interim data from the MyPEAK-1 trial, showing that all evaluable patients exhibited consistent signs of cardiac remodeling and symptom improvement, indicating the potential of TN-201 in treating MYBPC3-associated hypertrophic cardiomyopathy.
- Efficacy Assessment: As of the May 2026 data cutoff, six patients showed improvements across multiple clinical parameters, including echocardiographic measures of hypertrophy and symptom burden, with two patients in the higher-dose cohort demonstrating enhanced exercise capacity.
- Long-term Effects: Benefits for Cohort 1 patients were sustained for up to two years, while Cohort 2 patients exhibited greater symptom relief and improved cardiac function at earlier time points, suggesting durable and dose-responsive effects of TN-201.
- Regulatory Progress: TN-201 has received PRIME designation from the European Medicines Agency and is included in the FDA's Rare Disease Evidence Principles process, with Tenaya planning to expand enrollment for further long-term outcome characterization, highlighting the company's strategic positioning in cardiac disease treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNYA
Wall Street analysts forecast TNYA stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.728
Low
2.00
Averages
9.14
High
40.00
Current: 0.728
Low
2.00
Averages
9.14
High
40.00
About TNYA
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. Its pipeline includes TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy designed to deliver a working MYBPC3 gene to heart muscle cells via a single intravenous infusion, increasing MyBP-C protein levels to address the underlying cause of MYBPC3-associated HCM with the aim of halting or even reversing disease after a single dose. Its MyPEAK-1 Phase I b/2 clinical trial is an ongoing, multi-center, open-label, dose-escalating study designed to assess the safety, tolerability and clinical efficacy of a one-time intravenous infusion of TN-201 gene replacement therapy. TN-401 is its AAV9-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tenaya Therapeutics Reports Promising Interim Data on Gene Therapy for HCM
- Clinical Trial Progress: Tenaya Therapeutics presented interim data from the MyPEAK-1 trial, showing that all evaluable patients exhibited consistent signs of cardiac remodeling and symptom improvement, indicating the potential of TN-201 in treating MYBPC3-associated hypertrophic cardiomyopathy.
- Efficacy Assessment: As of the May 2026 data cutoff, six patients showed improvements across multiple clinical parameters, including echocardiographic measures of hypertrophy and symptom burden, with two patients in the higher-dose cohort demonstrating enhanced exercise capacity.
- Long-term Effects: Benefits for Cohort 1 patients were sustained for up to two years, while Cohort 2 patients exhibited greater symptom relief and improved cardiac function at earlier time points, suggesting durable and dose-responsive effects of TN-201.
- Regulatory Progress: TN-201 has received PRIME designation from the European Medicines Agency and is included in the FDA's Rare Disease Evidence Principles process, with Tenaya planning to expand enrollment for further long-term outcome characterization, highlighting the company's strategic positioning in cardiac disease treatment.
See More
Tenaya Therapeutics Presents Interim Data on TN-201 Gene Therapy for HCM
- Clinical Trial Update: Tenaya Therapeutics is presenting new interim data from the MyPEAK-1 Phase 1b/2 trial for TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy, with a webcast scheduled for June 3, 2026, enhancing clinical transparency and investor confidence.
- Disease Context: MYBPC3-associated hypertrophic cardiomyopathy is the most common genetic form, accounting for about 20% of the 120,000 patients in the U.S., highlighting the widespread nature of the condition and its severe impact on patients' quality of life, with no effective treatments addressing its genetic cause.
- Therapeutic Mechanism: TN-201 is an AAV9-based gene therapy designed to deliver a functional MYBPC3 gene to heart muscle cells via a single intravenous infusion, aiming to restore MyBP-C protein levels and potentially halt or reverse disease progression, which could have significant clinical implications.
- Market Performance: TNYA's stock has traded between $0.48 and $2.35 over the past year, closing at $0.79 on Tuesday with a 9.20% decline, while pre-market trading shows an increase to $0.84, up 6.33%, indicating market interest in its clinical advancements.
See More
Tenaya Therapeutics to Report Interim Data on TN-201 Gene Therapy for HCM
- Clinical Data Release: Tenaya Therapeutics will announce interim data from the MyPEAK™-1 trial on June 3, 2026, focusing on TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, potentially offering new treatment hope for 120,000 patients in the U.S.
- Live Webcast Event: The company will host a live webcast at 8:00 AM ET on the same day to review new data from MyPEAK™-1, allowing participants to register for access, thereby enhancing investor transparency and trust in the company's R&D progress.
- Disease Background: Variants in MYBPC3 are the leading genetic cause of hypertrophic cardiomyopathy, affecting approximately 20% of patients, leading to abnormal heart contraction and serious outcomes like heart failure and arrhythmias, indicating a strong market demand for TN-201.
- Therapy Design and Regulatory Progress: TN-201 is an AAV9-based gene therapy that has received FDA Fast Track, Orphan Drug, and Rare Pediatric Drug designations, highlighting its innovation and market potential in treating hypertrophic cardiomyopathy.
See More
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference
- Executive Participation: Tenaya Therapeutics' CEO Faraz Ali will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York, showcasing the company's innovative advancements in heart disease treatment, which is expected to attract investor interest.
- Live Webcast Arrangement: The presentation will be accessible via a live webcast on Tenaya's website, with an archived replay available for approximately 30 days post-conference, aimed at enhancing company transparency and attracting potential investors.
- Pipeline Highlights: Tenaya's pipeline includes gene therapies TN-201 and TN-401 for heart disease, along with the small molecule HDAC6 inhibitor TN-301, demonstrating the company's diversified strategy in heart disease treatment and potentially offering new options for patients.
- Company Mission and Vision: Tenaya is committed to discovering and developing curative therapies addressing the underlying causes of heart disease, leveraging unique genetic insights to show potential in treating both rare genetic disorders and prevalent heart conditions, further solidifying its leadership in the biotechnology sector.
See More
TN-401 Gene Therapy Significantly Reduces Arrhythmias in Patients
- Clinical Trial Results: In the RIDGE-1 clinical trial, TN-401 gene therapy achieved an average 64% reduction in premature ventricular contractions (PVCs) among six patients, demonstrating the therapy's potential to transform current treatment paradigms for arrhythmias.
- Safety Assessment: TN-401 was well tolerated at both 3E13 vg/kg and 6E13 vg/kg doses, with all patients successfully tapering off immunosuppressants and no serious adverse events reported, indicating the therapy's safety and feasibility.
- Biomarker Evidence: Post-dose biopsies revealed effective transduction and expression of TN-401 in heart muscle cells, with DNA levels of 3.4 vg/dg and 3.8 vg/dg in Cohorts 1 and 2 respectively, further supporting its scientific basis for clinical application.
- Regulatory Recognition: The European Medicines Agency has granted TN-401 PRIME designation, highlighting the therapy's potential to address significant unmet medical needs in heart disease patients, which may expedite its path to market.
See More
Tenaya Therapeutics Announces RIDGE-1 Clinical Data Presentation at ASGCT 2026
- RIDGE-1 Clinical Trial Data: Tenaya Therapeutics will present new data from the RIDGE-1 trial of TN-401 at the ASGCT 2026 Annual Meeting, featuring safety and efficacy results from both 3E13 vg/kg and 6E13 vg/kg dose cohorts, which is expected to enhance interest in cardiac gene therapy.
- Gene Therapy Innovation: TN-401 aims to deliver a functional PKP2 gene to heart muscle cells using an AAV9 vector to address heart disease caused by PKP2 mutations, potentially offering treatment options for over 70,000 patients in the U.S.
- Multiple Poster Presentations: Tenaya will also showcase a survey on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 gene editing therapy at ASGCT, further promoting public awareness and scientific dialogue around gene therapy.
- Webcast Conference Call: Tenaya plans to host a webcast conference call to discuss the clinical data for TN-401 presented at ASGCT, aiming to attract attention from investors and the medical community, thereby enhancing the company's influence in the gene therapy sector.
See More
Tenaya Therapeutics Reports Promising Interim Data on Gene Therapy for HCM
- Clinical Trial Progress: Tenaya Therapeutics presented interim data from the MyPEAK-1 trial, showing that all evaluable patients exhibited consistent signs of cardiac remodeling and symptom improvement, indicating the potential of TN-201 in treating MYBPC3-associated hypertrophic cardiomyopathy.
- Efficacy Assessment: As of the May 2026 data cutoff, six patients showed improvements across multiple clinical parameters, including echocardiographic measures of hypertrophy and symptom burden, with two patients in the higher-dose cohort demonstrating enhanced exercise capacity.
- Long-term Effects: Benefits for Cohort 1 patients were sustained for up to two years, while Cohort 2 patients exhibited greater symptom relief and improved cardiac function at earlier time points, suggesting durable and dose-responsive effects of TN-201.
- Regulatory Progress: TN-201 has received PRIME designation from the European Medicines Agency and is included in the FDA's Rare Disease Evidence Principles process, with Tenaya planning to expand enrollment for further long-term outcome characterization, highlighting the company's strategic positioning in cardiac disease treatment.
See More
Tenaya Therapeutics Presents Interim Data on TN-201 Gene Therapy for HCM
- Clinical Trial Update: Tenaya Therapeutics is presenting new interim data from the MyPEAK-1 Phase 1b/2 trial for TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy, with a webcast scheduled for June 3, 2026, enhancing clinical transparency and investor confidence.
- Disease Context: MYBPC3-associated hypertrophic cardiomyopathy is the most common genetic form, accounting for about 20% of the 120,000 patients in the U.S., highlighting the widespread nature of the condition and its severe impact on patients' quality of life, with no effective treatments addressing its genetic cause.
- Therapeutic Mechanism: TN-201 is an AAV9-based gene therapy designed to deliver a functional MYBPC3 gene to heart muscle cells via a single intravenous infusion, aiming to restore MyBP-C protein levels and potentially halt or reverse disease progression, which could have significant clinical implications.
- Market Performance: TNYA's stock has traded between $0.48 and $2.35 over the past year, closing at $0.79 on Tuesday with a 9.20% decline, while pre-market trading shows an increase to $0.84, up 6.33%, indicating market interest in its clinical advancements.
See More
Tenaya Therapeutics to Report Interim Data on TN-201 Gene Therapy for HCM
- Clinical Data Release: Tenaya Therapeutics will announce interim data from the MyPEAK™-1 trial on June 3, 2026, focusing on TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, potentially offering new treatment hope for 120,000 patients in the U.S.
- Live Webcast Event: The company will host a live webcast at 8:00 AM ET on the same day to review new data from MyPEAK™-1, allowing participants to register for access, thereby enhancing investor transparency and trust in the company's R&D progress.
- Disease Background: Variants in MYBPC3 are the leading genetic cause of hypertrophic cardiomyopathy, affecting approximately 20% of patients, leading to abnormal heart contraction and serious outcomes like heart failure and arrhythmias, indicating a strong market demand for TN-201.
- Therapy Design and Regulatory Progress: TN-201 is an AAV9-based gene therapy that has received FDA Fast Track, Orphan Drug, and Rare Pediatric Drug designations, highlighting its innovation and market potential in treating hypertrophic cardiomyopathy.
See More
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference
- Executive Participation: Tenaya Therapeutics' CEO Faraz Ali will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York, showcasing the company's innovative advancements in heart disease treatment, which is expected to attract investor interest.
- Live Webcast Arrangement: The presentation will be accessible via a live webcast on Tenaya's website, with an archived replay available for approximately 30 days post-conference, aimed at enhancing company transparency and attracting potential investors.
- Pipeline Highlights: Tenaya's pipeline includes gene therapies TN-201 and TN-401 for heart disease, along with the small molecule HDAC6 inhibitor TN-301, demonstrating the company's diversified strategy in heart disease treatment and potentially offering new options for patients.
- Company Mission and Vision: Tenaya is committed to discovering and developing curative therapies addressing the underlying causes of heart disease, leveraging unique genetic insights to show potential in treating both rare genetic disorders and prevalent heart conditions, further solidifying its leadership in the biotechnology sector.
See More
TN-401 Gene Therapy Significantly Reduces Arrhythmias in Patients
- Clinical Trial Results: In the RIDGE-1 clinical trial, TN-401 gene therapy achieved an average 64% reduction in premature ventricular contractions (PVCs) among six patients, demonstrating the therapy's potential to transform current treatment paradigms for arrhythmias.
- Safety Assessment: TN-401 was well tolerated at both 3E13 vg/kg and 6E13 vg/kg doses, with all patients successfully tapering off immunosuppressants and no serious adverse events reported, indicating the therapy's safety and feasibility.
- Biomarker Evidence: Post-dose biopsies revealed effective transduction and expression of TN-401 in heart muscle cells, with DNA levels of 3.4 vg/dg and 3.8 vg/dg in Cohorts 1 and 2 respectively, further supporting its scientific basis for clinical application.
- Regulatory Recognition: The European Medicines Agency has granted TN-401 PRIME designation, highlighting the therapy's potential to address significant unmet medical needs in heart disease patients, which may expedite its path to market.
See More
Tenaya Therapeutics Announces RIDGE-1 Clinical Data Presentation at ASGCT 2026
- RIDGE-1 Clinical Trial Data: Tenaya Therapeutics will present new data from the RIDGE-1 trial of TN-401 at the ASGCT 2026 Annual Meeting, featuring safety and efficacy results from both 3E13 vg/kg and 6E13 vg/kg dose cohorts, which is expected to enhance interest in cardiac gene therapy.
- Gene Therapy Innovation: TN-401 aims to deliver a functional PKP2 gene to heart muscle cells using an AAV9 vector to address heart disease caused by PKP2 mutations, potentially offering treatment options for over 70,000 patients in the U.S.
- Multiple Poster Presentations: Tenaya will also showcase a survey on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 gene editing therapy at ASGCT, further promoting public awareness and scientific dialogue around gene therapy.
- Webcast Conference Call: Tenaya plans to host a webcast conference call to discuss the clinical data for TN-401 presented at ASGCT, aiming to attract attention from investors and the medical community, thereby enhancing the company's influence in the gene therapy sector.
See More
